Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73,819,979
-
Total 13F shares
-
9,525,387
-
Share change
-
+319,630
-
Total reported value
-
$335,356,371
-
Put/Call ratio
-
7.5%
-
Price per share
-
$35.21
-
Number of holders
-
78
-
Value change
-
+$11,917,055
-
Number of buys
-
27
-
Number of sells
-
34
Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q1 2021
As of 31 Mar 2021,
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) was held by
78 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,525,387 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Avoro Capital Advisors LLC, BlackRock Inc., VR Adviser, LLC, VANGUARD GROUP INC, PARSONS CAPITAL MANAGEMENT INC/RI, STATE STREET CORP, Ikarian Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, and FRANKLIN RESOURCES INC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.